Pirfenidone is Efficacious in Patients with Idiopathic Pulmonary Fibrosis (IPF) and Mild Restrictive Disease
U Costabel, C Albera, WZ Bradford, EA Fagan, I Glaspole, MK Glassberg, E Gorina, D Kardatzke, TE King, L Lancaster, DJ Lederer, SD Nathan, CA Pereira, D Spirig, JJ Swigris, D Valeyre, PW Noble · Pneumologie · 2016 · Heft 02
Bibliografische Angaben
Zusammenfassung
Introduction: IPF is a progressive, irreversible and fatal disease. Early treatment when lung function is relatively preserved may have beneficial outcomes. Here we investigated the efficacy of pirfenidone (PFD) in patients stratified by mild vs more pronounced restrictive disease as well as by GAP stage. Methods: Efficacy outcomes (FVC, 6MWD, UCSD SOBQ) were analysed at 12 months in patients randomised to PFD 2403 mg/d or placebo (PBO) in the pooled CAPACITY/ASCEND population (N = 1247), stratified into two different sets of subgroups defined by dichotomisation of baseline FVC (≥80%, < 80%) and GAP stage (GAP1,…
